



Dupixent in Egypt

The EDA named-patient coordination pathway — indicative 2026

IMMUNOLOGY · TYPE-2 INFLAMMATION IL-4RA

The clinical situation

Dupixent (dupilumab) is an FDA-approved human monoclonal antibody against IL-4 receptor alpha that blocks the shared IL-4 and IL-13 signalling axis, with indications spanning atopic dermatitis, severe asthma, eosinophilic oesophagitis, prurigo nodularis, and chronic spontaneous urticaria. Developed by Regeneron and Sanofi. Where a specific indication, age band, presentation, or supply need is not met through the locally available channel in Egypt, a named-patient import pathway may be appropriate. Administration is subcutaneous, with a loading dose followed by every-two-weeks or every-four-weeks maintenance depending on indication, age, and weight.

The pathway, 5 steps

- 1 Consultation & clinical rationale.** Your treating dermatologist, pulmonologist, allergist, or gastroenterologist documents diagnosis, age/weight, prior therapy, and the reason local supply does not meet the need.
- 2 EDA named-patient application.** Physician or importing pharmacy files Egyptian licence verification, patient reference, dosing plan, and chain-of-custody documentation.
- 3 US-side sourcing & logistics.** Reserve Meds coordinates product through our US-licensed DSCSA-compliant specialty wholesale partner under documented chain of custody.
- 4 Cold-chain shipment & arrival.** Temperature-controlled transport; the importer of record receives and hands off per your physician's protocol.
- 5 Initiation & re-supply cadence.** Most patients or caregivers self-inject at home after training; Reserve Meds supports the q2w / q4w maintenance cadence.

Indicative economics

Reference US cash-pay range: USD 3,500–4,000 per month at typical adult dosing (paediatric weight-banded dosing often lower; Reserve Meds issues a transparent delivered quote at intake).

Indicative first-shipment timing

10–21 days from a complete EDA application to first shipment, once cohort intake opens. Indicative — not guaranteed.

Reserve Meds's role

Sourcing. US-licensed specialty wholesale partner, DSCSA chain-of-custody. **Documentation.** Physician documentation kit keyed to EDA review. **Logistics.** Cold-chain shipment with importer-of-record handling. **Concierge case lead.** Named point of contact for family and specialist team; we coordinate alongside your existing academic-centre relationships, not in competition. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating physician.

COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST

Join the Dupixent × Egypt first-cohort waitlist. *Our concierge reaches out as we open intake.*

reservemed.com/access-guides/dupixent-egypt.html



SCAN TO JOIN

Reserve Meds · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.

reservemed.com · hello@reservemed.com · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team